| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Bax (Kd = 15.0 μM)
|
|---|---|
| ln Vitro |
BAX activation inhibitor 1 (BAI1) demonstrates inhibition of tBID-induced BAX-mediated membrane permeabilization in a dose dependent manner with an IC50 of 3.3 μM. At an original allosteric site, BAI1 binds to monomeric BAX. While BAI1 does not directly compete with the activator to inhibit conformational activation and oligomerization of BAX in solution, it does so through an allosteric mechanism that favors the inactive BAX. Additionally, BAI1 inhibited BAX membrane association and translocation brought about by tBID (IC50 = 5 ± 1 μΜ) or BIM SAHB (IC50 = 2 ± 1 μΜ) in a dose-dependent manner and with an IC50 that was comparable to BAX-mediated liposomal release. Only BAX-dependent cell death is inhibited by BAI1[1].
|
| Cell Assay |
Caspase 3/7 assay of WT MEFs after pro-apoptotic TNF/CHX treatment, whether BAI1 was given in conjunction with it or not at the recommended doses for 8 hours.
|
| References | |
| Additional Infomation |
1-(3,6-dibromo-9-carbazolyl)-3-(1-piperazinyl)-2-propanol is a member of bromobenzenes and a member of biphenyls.
|
| Molecular Formula |
C19H21BR2N3O
|
|---|---|
| Molecular Weight |
540.11942
|
| Exact Mass |
536.958
|
| Elemental Analysis |
C, 48.85; H, 4.53; Br, 34.21; N, 8.99; O, 3.42
|
| CAS # |
335165-68-9
|
| Related CAS # |
335165-68-9
|
| PubChem CID |
2729027
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
388.1ºC at 760 mmHg
|
| Flash Point |
188.5ºC
|
| LogP |
5.456
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
422
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(CN1CCNCC1)CN2C3=C(C4=C2C=CC(Br)=C4)C=C(Br)C=C3
|
| InChi Key |
KUUJEXLRLIPQQJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H21Br2N3O/c20-13-1-3-18-16(9-13)17-10-14(21)2-4-19(17)24(18)12-15(25)11-23-7-5-22-6-8-23/h1-4,9-10,15,22,25H,5-8,11-12H2
|
| Chemical Name |
1-(3,6-dibromocarbazol-9-yl)-3-piperazin-1-ylpropan-2-ol
|
| Synonyms |
BAI1; BAI 1; BAI-1; Brain-specific angiogenesis inhibitor 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~18 mg/mL (~38.5 mM)
Ethanol: ~3 mg/mL (~6.4 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.87 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.87 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8514 mL | 9.2572 mL | 18.5144 mL | |
| 5 mM | 0.3703 mL | 1.8514 mL | 3.7029 mL | |
| 10 mM | 0.1851 mL | 0.9257 mL | 1.8514 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
